CA2295049A1 - Methods to potentiate intravenous estramustine phosphate - Google Patents

Methods to potentiate intravenous estramustine phosphate Download PDF

Info

Publication number
CA2295049A1
CA2295049A1 CA002295049A CA2295049A CA2295049A1 CA 2295049 A1 CA2295049 A1 CA 2295049A1 CA 002295049 A CA002295049 A CA 002295049A CA 2295049 A CA2295049 A CA 2295049A CA 2295049 A1 CA2295049 A1 CA 2295049A1
Authority
CA
Canada
Prior art keywords
estramustine
cancer
estramustine phosphate
administered
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295049A
Other languages
English (en)
French (fr)
Inventor
Beryl Asp
Michael S. Kopreski
Bo Fredholm
Per-Olv Gunnarsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2295049A1 publication Critical patent/CA2295049A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002295049A 1998-03-27 1999-03-26 Methods to potentiate intravenous estramustine phosphate Abandoned CA2295049A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7954298P 1998-03-27 1998-03-27
US60/079,542 1998-03-27
PCT/US1999/004275 WO1999049869A1 (en) 1998-03-27 1999-03-26 Methods to potentiate intravenous estramustine phosphate

Publications (1)

Publication Number Publication Date
CA2295049A1 true CA2295049A1 (en) 1999-10-07

Family

ID=22151209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295049A Abandoned CA2295049A1 (en) 1998-03-27 1999-03-26 Methods to potentiate intravenous estramustine phosphate

Country Status (16)

Country Link
EP (1) EP1003521A4 (ja)
JP (1) JP2001508810A (ja)
KR (1) KR20010021656A (ja)
CN (2) CN1273530A (ja)
AU (1) AU750010B2 (ja)
BR (1) BR9906425A (ja)
CA (1) CA2295049A1 (ja)
EA (1) EA004647B1 (ja)
HU (1) HUP0200547A3 (ja)
ID (1) ID24504A (ja)
IL (1) IL133612A0 (ja)
NO (1) NO20002343L (ja)
NZ (1) NZ501987A (ja)
PL (1) PL342969A1 (ja)
WO (1) WO1999049869A1 (ja)
ZA (1) ZA997821B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
US6436913B1 (en) * 2000-07-25 2002-08-20 Pharmacia & Upjohn Company Use of estramustine phosphate in the treatment of bone metastasis
RU2471511C1 (ru) * 2011-05-04 2013-01-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РНИОИ" Минздравсоцразвития России) Способ лечения метастазов в печень рака толстой кишки

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617292A (ja) * 1984-06-20 1986-01-13 Japan Atom Energy Res Inst 制癌剤を結合させたエストラサイト系化合物を製造する方法
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.

Also Published As

Publication number Publication date
HUP0200547A2 (hu) 2002-07-29
CN1636598A (zh) 2005-07-13
NO20002343D0 (no) 2000-05-04
WO1999049869A1 (en) 1999-10-07
CN1273530A (zh) 2000-11-15
PL342969A1 (en) 2001-07-16
IL133612A0 (en) 2001-04-30
EA004647B1 (ru) 2004-06-24
EP1003521A1 (en) 2000-05-31
NO20002343L (no) 2000-05-04
JP2001508810A (ja) 2001-07-03
AU750010B2 (en) 2002-07-11
NZ501987A (en) 2002-10-25
ZA997821B (en) 2000-08-01
EA199901081A1 (ru) 2000-12-25
ID24504A (id) 2000-07-20
AU3353399A (en) 1999-10-18
KR20010021656A (ko) 2001-03-15
HUP0200547A3 (en) 2003-07-28
BR9906425A (pt) 2000-07-11
EP1003521A4 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
US6146659A (en) Method of administering liposomal encapsulated taxane
US6461637B1 (en) Method of administering liposomal encapsulated taxane
KR20080091747A (ko) 알부민 안정화된 파클리탁셀을 포함하는 고형성 종양 치료용 약물 제형
JP2007518805A5 (ja)
AU744095B2 (en) Methods and compositions for treatment of ovarian cancer
US6849616B1 (en) Methods to potentiate intravenous estramustine phosphate
AU750010B2 (en) Methods to potentiate intravenous estramustine phosphate
de Souza et al. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
MXPA00000198A (en) Methods to potentiate intravenous estramustine phosphate
AUen Stealth® Liposomes as a Drug Sustained Release System for 1-PD-Arabinosy lfuranosy lcytosine (Cytosine Arabinoside)
KR20030019612A (ko) 골전이 치료에서 에스트라무스틴 포스페이트의 용도
CZ465599A3 (cs) Způsoby potenciace intravenosního estramustinfosfátu
US7314637B1 (en) Method of administering liposomal encapsulated taxane
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
Du Bois et al. Clinical course and management of paclitaxel extravasation
Diaz-Rubio et al. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide): a randomized, double-blind, cross-over trial
Tsavaris et al. A simplified premedication schedule for 1-hour paclitaxel administration
WO2001070220A1 (en) A method of administering liposomal encapsulated taxane
Pienta et al. Oral chemotherapy in the treatment of hormone-refractory prostate cancer
CN102716095A (zh) 一种紫杉醇囊泡型磷脂凝胶注射剂
Sweeney Indiana University Cancer Pavilion, Indianapolis
MXPA00002170A (en) A method of administering liposomal encapsulated taxane
AU2002364165A1 (en) Process for affecting neurologic progression
CZ339299A3 (cs) Použití taxanu pro léčení rakoviny vaječníků

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued